Russell Investments Group Ltd. Takes $327,000 Position in Pro-Dex, Inc. (NASDAQ:PDEX)

Russell Investments Group Ltd. acquired a new stake in Pro-Dex, Inc. (NASDAQ:PDEX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 6,999 shares of the medical instruments supplier's stock, valued at approximately $327,000. Russell Investments Group Ltd. owned approximately 0.21% of Pro-Dex as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of PDEX. Bank of New York Mellon Corp bought a new stake in Pro-Dex during the 4th quarter worth $202,000. Trexquant Investment LP bought a new stake in shares of Pro-Dex during the fourth quarter worth about $252,000. Integrated Quantitative Investments LLC acquired a new position in shares of Pro-Dex in the fourth quarter valued at approximately $254,000. Arrowstreet Capital Limited Partnership acquired a new position in shares of Pro-Dex in the fourth quarter valued at approximately $255,000. Finally, American Century Companies Inc. bought a new position in Pro-Dex in the 4th quarter valued at approximately $558,000. Institutional investors and hedge funds own 15.28% of the company's stock.

Analyst Ratings Changes

Separately, StockNews.com lowered shares of Pro-Dex from a "buy" rating to a "hold" rating in a report on Wednesday, March 12th.

Pro-Dex Trading Down 1.1 %

NASDAQ:PDEX traded down $0.72 during trading hours on Wednesday, hitting $65.68. 31,957 shares of the company were exchanged, compared to its average volume of 26,208. The company has a fifty day simple moving average of $51.24 and a 200 day simple moving average of $45.23. Pro-Dex, Inc. has a one year low of $16.84 and a one year high of $70.26. The stock has a market capitalization of $214.18 million, a price-to-earnings ratio of 32.68 and a beta of 0.40. The company has a current ratio of 2.58, a quick ratio of 1.44 and a debt-to-equity ratio of 0.33.

Pro-Dex (NASDAQ:PDEX - Get Free Report) last posted its quarterly earnings data on Thursday, January 30th. The medical instruments supplier reported $0.61 EPS for the quarter, topping analysts' consensus estimates of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. Sell-side analysts expect that Pro-Dex, Inc. will post 2 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Raymond E. Cabillot sold 1,100 shares of Pro-Dex stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $45.01, for a total value of $49,511.00. Following the completion of the sale, the director now owns 318,652 shares in the company, valued at $14,342,526.52. The trade was a 0.34 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Over the last three months, insiders sold 22,483 shares of company stock worth $1,080,693. 47.50% of the stock is owned by corporate insiders.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.